Jacobson Pharma Leads HKD 6 Million JV for Specialty Drug Distribution
China-based Jacobson Pharma Corporation (HKG: 2633), Ban Loong Holdings Ltd (HKG: 0030), and JBM (Healthcare)...
Hansoh Pharmaceutical’s Ameile Accepted for UK Regulatory Review
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that a Marketing Authorization Application (MAA)...
MegaRobo Secures USD 300 Million in Series C Round Led by Goldman Sachs
Beijing-based MegaRobo Technologies, a company applying robotics and artificial intelligence (AI) in the life sciences...
China Issues Monkeypox Diagnosis Guidelines Amid Global Outbreaks
China’s National Health Commission (NHC) has formulated and released the “Monkeypox Diagnosis and Treatment Guidelines”...
Quoin Pharmaceuticals Partners with WinHealth for Rare Disease Treatments in Greater China
US-based rare disease specialist Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) announced a licensing and distribution agreement...
US Bipartisan Bill Seeks to Regulate Investments in Chinese High-Tech Firms
US senators are preparing a bipartisan bill that would require US investors targeting Chinese high-tech...
Alphamab Oncology Doses First Patient in Phase I Trial for PD-L1/OX40 Bispecific Antibody KN052
China-based Alphamab Oncology (HKG: 9966) has announced the dosing of the first patient in a...
Walvax Biotechnology Halts EV71 Vaccine Development Amid Changing Disease Trends
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced the decision to terminate a clinical...
Jiangsu Hengrui Medicine’s Hetrombopag Olamine Receives FDA Orphan Drug Designation for ITP
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that it has received orphan...
WuXi AppTec Faces Shareholder Divestment of Up to 3% Stake
China-based Contract Research Organization (CRO) WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has disclosed...
Zai Lab Ltd Makes FcRn Antagonist Efgartigimod Available for Myasthenia Gravis Treatment
Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the availability of efgartigimod, the world’s...
Bristol-Myers Squibb Launches Reblozyl in China for β-Thalassemia Treatment
US pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the commercial launch of its...
China NT Pharma Group Company Ltd Inks Licensing Deal for Monoclonal Antibodies
China-based China NT Pharma Group Company Ltd (HKG: 1011) has announced a potential acquisition agreement...
Clover Biopharmaceuticals Initiates SCB-219M Clinical Study for CIT Treatment
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) has announced the first subject dosing in a Phase...
Changchun High & New Technology’s Jinnamab Approved for AOSD Clinical Study by US FDA
China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) has announced that it...
Ferring and I-Mab Expand Olamkicept Collaboration for Inflammatory Diseases
Swiss pharmaceutical company Ferring Pharmaceuticals has announced a strategic collaboration with China’s I-Mab Inc. (NASDAQ:...
Soaring Costs of Cynomolgus Monkeys Impact China’s Biologic Drug Development
Cynomolgus monkeys, or macaques, used in laboratory experiments have seen their value skyrocket due to...
Shanghai Henlius Partners with Organon for Global Biosimilar Commercialization
China-based Shanghai Henlius Biotech, Inc. (HKG: 2696) has entered into a licensing and supply agreement...
BeiGene’s Brukinsa Faces Three-Month FDA Approval Delay for CLL/SLL Indication
China-based biotech company BeiGene Inc. (Nasdaq: BGNE) will experience a three-month delay in its pursuit...
Junshi Biosciences Receives NMPA Approval for Fourth-Generation EGFR Inhibitor WJ13404
Shanghai-based biotech Junshi Biosciences (HKG: 1877, SHA: 688180) has received approval from China’s National Medical...